Μ
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
M. D. Willard's research focuses on oncological treatments, particularly investigating the efficacy and safety of novel therapeutic agents for non-small cell lung cancer (NSCLC) with specific genetic mutations. Recent publications highlight the evaluation of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC, including those with active brain metastases. Studies have examined olomorasib in combination with chemotherapy and immunotherapy as a first-line treatment, assessing both efficacy and safety profiles. Additionally, Willard's work has explored psychosocial factors related to electronic cigarette use within the military population.
With a scholarly profile including an h-index of 27, 65 total publications, and 2,379 citations, Willard is recognized as a highly cited researcher. The active laboratory website suggests ongoing research activities and potential for continued contributions in the field of cancer therapeutics and related health behaviors.
Metrics
- h-index: 27
- Publications: 65
- Citations: 2,379
Selected Publications
-
Psychosocial Factors and Electronic Cigarette Use in the Military Population (2025)
Collaboration Network
Top Collaborators
Antoine Hollebecque
Institut Gustave Roussy (FR)
2 shared publications
- Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
- 1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases
A.I. Spira
Virginia Cancer Specialists (US)
2 shared publications
- Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
- 1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases
J. Nicholas Bodor
Fox Chase Cancer Center (US)
2 shared publications
- Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
- OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01
Aliza K. Fink
Eli Lilly (United States) (US)
2 shared publications
- Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
- OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01
K. Dragnev
Dartmouth–Hitchcock Medical Center (US)
2 shared publications
- Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
- OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01
Garrett Sherwood
Novant Health (US)
2 shared publications
- OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01
- 1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases
Claudia P. Barone
1 shared publication
- Psychosocial Factors and Electronic Cigarette Use in the Military Population
Brittany Beasley
1 shared publication
- Psychosocial Factors and Electronic Cigarette Use in the Military Population
Lana M. Brown
1 shared publication
- Psychosocial Factors and Electronic Cigarette Use in the Military Population
Pamela deGravelles
1 shared publication
- Psychosocial Factors and Electronic Cigarette Use in the Military Population
James P. Selig
1 shared publication
In database
- Psychosocial Factors and Electronic Cigarette Use in the Military Population
Yasuhiro Fujiwara
Aichi Cancer Center (JP)
1 shared publication
- Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
N. Ammakkanavar
Community Health Network (US)
1 shared publication
- Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
Y Goroff
Memorial Sloan Kettering Cancer Center (US)
1 shared publication
- Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
Dong Hoon Lee
Ulsan College (KR)
1 shared publication
- Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
Similar Researchers
Based on overlapping research topics
Eric Peterson
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health Sciences Research and Education
Pharmacological Effects and Toxicity Studies
Ples Spradley
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Lung Cancer Diagnosis and Treatment
Health Sciences Research and Education
M. Edward F. H. Yeh
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health Sciences Research and Education
Cancer-related molecular mechanisms research
Linh‐Chi Ho
Arkansas State University
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Cancer-related molecular mechanisms research
Sofia Syed
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Behavioral and Psychological Studies
Health Sciences Research and Education
K. Arnaoutakis
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health Sciences Research and Education
Health and Medical Research Impacts